A nasal spray developed by an Australian firm has shown positive results in reducing the growth of the SARS-CoV-2 virus, which causes COVID19 infection. This spray has been made by an Australian biotech company called Ena Respiratory. The nasal spray is supposed to improve the human immune system to fight against normal cold and flu. The latest trial of the nasal spray has been done on ferrets. In the study, it has been proved effective to reduce the growth of the SARS-CoV-2 virus in ferrets. This nasal spray is called INNA-051. Experts have said that it can be used as complementary medicine along with the vaccine. They have claimed that this nasal spray can reduce virus replication by 96 percent. This study has been led by the British government agency, Public Health England.
Experts are planning to conduct a human trial of INNA-051 in another four months. However, the toxicity studies and regulatory approval for the nasal spray have not been done yet. The company Ena Respiratory has collected a sum of $8.24 million for the development of this nasal spray. The firm has partnered with investors like Brandon Capital Ltd, Australian Federal Government, Pension Funds, and Biotech giant CSL Ltd. Many firms around the world have ventured into the development of the COVID19 vaccine. Australia has invested billions of funds to get a vaccine for COVID19 teaming up with many drug companies.
The officials of the firm have said that INNA-051 would effectively reduce the severity of the infection among the COVID19 patients. It will not allow the disease to grow beyond mild symptoms, so people with the infection will not be able to pass on the infection rapidly. It is quite useful for vulnerable people of the community, said the experts. It will put a halt to the rapid community transmission of the virus as well. Australia has reported more than 27000 COVID19 cases and nearly 875 deaths so far, which is quite less than the cases reported in most of the developed nations.